Abivax SA (ABVX)

Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)June 2, 2026 9:20 PM
PR Newswire (US) Jefferies downgraded Abivax from Buy to Hold and slashed its price target by nearly 44% after rare cancer cases emerged in the company's Phase 3 ulcerative colitis trial -- shares more than 40% of their value in a single session.NEW YORK, June 2, 2026 /PRNewswire/ -- Abivax (NASDAQ: ABVX) shareholders more than to 40% of their investment value on June 2, 2026, as the stock plunged from a pre-announcement close of approximately $129.69 to as low as $71 per share midday after rare malignancy cases surfaced in the company's Phase 3 ABTECT ulcerative colitis trial for obefazimod. Shareholders who lost money on ABVX are encouraged to submit their information to SueWallSt. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt. The market reaction was swift and severe. Trading volume surged to more than eight times the daily average on June 2. Jefferies downgraded ABVX from Buy to Hold and cut its price target from $160 to $90 -- a 43.75% reduction -- citing the cancer signal as a material overhang on the stock's outlook. Short interest climbed to approximately 12% of the float within 24 hours of the disclosure.Notably, the stock had initially rallied approximately 20% in after-hours trading on June 1 when the Phase 3 efficacy data were first released. Within hours, as the rare malignancy cases in the treatment arm received broader coverage, the rally reversed entirely and shares collapsed through the prior close. By the midday trading on June 2, ABVX had fallen more than 45%, erasing all gains since mid-August, 2025.If you purchased Abivax shares and suffered a loss, click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.ABOUT THE FIRM -- For over two decades, SueWallSt has represented shareholders in securities investigations and recoveries. Ranked in ISS Top 50 for seven consecutive years.Frequently Asked Questions About the ABVX InvestigationQ: Who is conducting the ABVX investigation? A: SueWallSt is investigating potential securities law violations on behalf of investors who purchased ABVX securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.Q: How much did ABVX stock drop? A: Shares fell approximately 40-45% -- a decline of nearly $60 per share from the previous day's close -- after the company disclosed rare cancer cases in its Phase 3 ulcerative colitis trial. Investors who purchased shares before the disclosure may be eligible for recovery.Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Abivax adequately disclosed material safety risks associated with the Phase 3 ABTECT trial for obefazimod. When the cancer signal received broader attention, the stock price declined sharply.Q: What do ABVX investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at jlevi@SueWallSt.com or (888) SueWallSt. No immediate action is required to remain eligible to participate in the investigation.Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.Q: What if I already sold my ABVX shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ABVX and sold at a loss may still participate in the investigation.Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi @Icons1 View original content to download multimedia:https://www.prnewswire.com/news-releases/abivax-investigation-initiated-suewallst-investigates-the-officers-and-directors-of-abivax-abvx-302789317.htmlSOURCE SueWallSt.com Original: Abivax Investigation Initiated: SueWallSt Investigates the Officers and Directors of Abivax (ABVX)

Abivax Shares Tumble Despite Strong Ulcerative Colitis Trial Results as Safety Concerns Emerge (ABVX)June 2, 2026 6:23 AM
IH Market News Abivax (NASDAQ:ABVX) shares fell sharply on Tuesday after investors focused on reports of rare malignancy cases in a late-stage clinical trial, overshadowing better-than-expected efficacy results for the company’s experimental ulcerative colitis treatment. The Paris-listed biotech company saw its stock drop more than 32% in early European trading by 07:34 GMT. Obefazimod Delivers Strong Remission Rates Results from the 44-week study showed that obefazimod achieved clinical remission in approximately half of treated patients across both dosage groups. Patients receiving the 25-milligram dose recorded a remission rate of 50.8%, while those treated with the 50-milligram dose achieved a rate of 51.3%. By comparison, only 10.4% of patients in the placebo group reached clinical remission. The outcome significantly exceeded market expectations and appeared to compare favorably with currently available treatment options for ulcerative colitis. Rare Malignancy Cases Weigh on Investor Sentiment While obefazimod was generally well tolerated throughout the study, investor attention shifted toward a small number of malignancy cases reported during the trial. The cases were described as rare, isolated events and were not considered related to the treatment. Nevertheless, their inclusion in the study data raised concerns among investors and contributed to the sharp decline in the company’s share price. Analysts Highlight Strong Efficacy but Note Added Uncertainty Analysts at Stifel said the study results reinforced the competitive positioning of obefazimod within the ulcerative colitis treatment landscape. The trial results were “clearly above expectations and outperforming current therapies, confirming the differentiated profile of obefazimod,” Stifel analysts led by Damien Choplain said in a note, adding that the malignancy events “introduced uncertainty and put the share price under pressure.” The analysts also suggested that the reported cases may ultimately have limited implications for the drug’s overall safety profile. “While the malignancy signal cannot be ignored, we view it as a potential labelling overhang rather than evidence of a clear causal safety risk,” they wrote. Abivax stock price Original: Abivax Shares Tumble Despite Strong Ulcerative Colitis Trial Results as Safety Concerns Emerge (ABVX)

I owe it all to #DDAmanda ...............https://DDAmanda.com

Z

It's ok, brother, I just posted that news to you because you recommended it at $9.88. Holy shyt, you are fantastic! Kick Arzz buddy!🤣

Ok.......just a bit pricey for me though........not enough % of significant gains.........

Z

Abivax SA’s shares surged as much as 31% in early Paris trading as speculation mounted over a possible takeover of the French biotech.

Abivax is entering a pivotal year, with a slate of clinical trial results expected for the experimental drug obefazimod. The view that the company would make an attractive acquisition target has helped drive up Abivax’s shares by some 1900% in the past 12 months.

France’s La Lettre reported on Monday that Eli Lilly & Co. is ready to offer €15 billion ($17.5 billion) to buy the firm, but is waiting for an indication from the French Finance Ministry as to whether a takeover would be subject to foreign investment controls.

Abivax Shares Extend Rally Amid Takeover Speculation

$ABVX - #DDAmanda Chart:

#DDAmanda finds these before they run.





Z

bingo$

You can buy to short this ticker . Mulah KaChing ...

Another club only stock that goes up for no reason at all. Everyone in the club got the 4am talking points yesterday to buy. Now they run it up from retail investors that will have the rug pulled from them and left holding bags of worthless garbage. No, I never got the memo because I am not a club member. Honest people get ripped off in life while criminals make all the money.

Moolah and KaChing $$$$ Money Making Machine Lotto Play

$ABVX: I am impressed...................

You are getting better and better of being ahead of the party.

WELL DONEEEEeeeeeeeeeeeeeee

Was hoping to see some options contracts on this one........... but I guess that should change soon.

If $ABVX can surge like this........ hoping to see something similar with WhiteHawk Therapeutics to do something similar $WHWK

GO $ABVX

VERY AMAZING, IT OPENED AT $56, LOW $56 AND HIGH $56. WAS THAT RIGHT****GOOD FOR THOSE ALREADY IN BEFORE THE NEWS.

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
https://www.otcmarkets.com/stock/ABVX/news/Abivax-Announces-Positive-Phase-3-Results-from-Both-ABTECT-8-Week-Induction-Trials-Investigating-Obefazimod-its-First-in?e&id=3280199

You're here 😃 LOL

But great news and amazing green candle (have no position here).

==================

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

July 22, 2025

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

https://ih.advfn.com/stock-market/NASDAQ/abivax-ABVX/stock-news/96476150/abivax-announces-positive-phase-3-results-from-bot

$ABVX

no one here huh. interesting

ABVX under $15